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Abstract:
Background:Metabolic syndrome is an indicator of cardiovascular disease and diabetes.
The evaluation of the prevalence of dyslipidemia in the country as a major risk factor
for the prevention of coronary artery disease is essential for prevention of progressiorr.
The aim of this study rvas to evaluate the sensitivity and specificity of non HDL chol
diagnostic value for the diagnosis of metabolic syndrome In the urban cornmunit.v of
Kerman.
Methods: 5900 subjects women and men. 20 years old and above were studied in a
population based, cross sectional study. Waist circumference. blood pressure. blood
sugar, and blood lipids were measured and non HDL is calculated according to tire
definition. ROC analysis u,as used for determining the most suitable cut off point of non
HDL chol. The prevalence of metabolic syndrome was then assessed based on IDF.
NCEP criteria and the proposed criterion. and agreement among the three methods in
diagnosing people suffering from metabolic s1'ndrome \^'as examined.
Results:. The most suitable cut off point of non HDL chol for metabolic sy'ndrome
diagnosis was 154.5 in women and 146.5 in men. These level of non HDL chol had t}:e
highest specificity and sensitivity.
Conclusion: The use of non HDL chol has been helpful in predicting metabolr;
syndrome, and as a benchmark that can easily be calculated. it can be used to predict :i::
risk of cardiovascular disease and diabetes in patients u,ith metabolic syndrome. so i1-..:
recommendations It starls treatment and prevention in patients with metabolic srndroi:..
as soon as possible.
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